

**WEST****Generate Collection****Search Results - Record(s) 1 through 10 of 21 returned.** 1. Document ID: US 5932250 A

L2: Entry 1 of 21

File: USPT

Aug 3, 1999

US-PAT-NO: 5932250

DOCUMENT-IDENTIFIER: US 5932250 A

TITLE: Anti-cholesterolemic egg, vaccine and method for production, and use

DATE-ISSUED: August 3, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stolle; Ralph J.	Lebanon	OH	N/A	N/A
Beck; Lee R.	Lebanon	OH	N/A	N/A

US-CL-CURRENT: 424/581, 426/614, 800/8[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#) 2. Document ID: US 5919451 A

L2: Entry 2 of 21

File: USPT

Jul 6, 1999

US-PAT-NO: 5919451

DOCUMENT-IDENTIFIER: US 5919451 A

TITLE: Method of improving the growth or the efficiency of feed conversion of an animal and compositions for use therein

DATE-ISSUED: July 6, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cook; Mark E.	Madison	WI	N/A	N/A
Jerome; Daria L.	Frazee	MN	N/A	N/A

US-CL-CURRENT: 424/130.1, 106/124.1, 424/157.1, 424/158.1,  
424/442, 426/140, 426/657, 426/89, 530/388.2[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

3. Document ID: US 5904922 A

L2: Entry 3 of 21

File: USPT

May 18, 1999

US-PAT-NO: 5904922

DOCUMENT-IDENTIFIER: US 5904922 A

TITLE: Treatment with polyvalent antivenom containing immunoglobulin which is greater than 50% venom-reactive

DATE-ISSUED: May 18, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carroll; Sean B.	Cottage Grove	WI	N/A	N/A

US-CL-CURRENT: 424/130.1, 424/158.1, 424/542, 435/174, 435/178,  
435/180, 436/518, 436/529, 436/824, 514/2, 514/21, 530/387.1,  
530/389.1, 530/413, 530/810, 530/813, 530/856, 530/858

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

 4. Document ID: US 5853765 A

L2: Entry 4 of 21

File: USPT

Dec 29, 1998

US-PAT-NO: 5853765

DOCUMENT-IDENTIFIER: US 5853765 A

TITLE: Anti-cholesterolemic egg, vaccine and method for production, and use

DATE-ISSUED: December 29, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stolle; Ralph J.	Lebanon	OH	N/A	N/A
Beck; Lee R.	Lebanon	OH	N/A	N/A

US-CL-CURRENT: 424/581, 424/234.1, 424/282.1, 424/439

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

 5. Document ID: US 5849349 A

L2: Entry 5 of 21

File: USPT

Dec 15, 1998

US-PAT-NO: 5849349

DOCUMENT-IDENTIFIER: US 5849349 A

TITLE: Anti-cholesterolemic egg, vaccine and method for production, and use

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stolle; Ralph J.	Lebanon	OH	N/A	N/A
Beck; Lee R.	Lebanon	OH	N/A	N/A

US-CL-CURRENT: 426/614; 119/6.8, 424/157.1, 424/184.1, 424/234.1,  
424/581, 424/93.1, 800/8

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

6. Document ID: US 5772999 A

L2: Entry 6 of 21 File: USPT Jun 30, 1998

US-PAT-NO: 5772999

DOCUMENT-IDENTIFIER: US 5772999 A

TITLE: Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals

DATE-ISSUED: June 30, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Greenblatt; Hellen Chaya	Wilmington	DE	N/A	N/A
Adalsteinsson; Orn	Kennett Square	PA	N/A	N/A
Brodie; David Alan	East Windsor	NJ	N/A	N/A
Fitzpatrick-McElligott; Sandra G.	Rose Valley	PA	N/A	N/A

US-CL-CURRENT: 424/157.1; 424/158.1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

7. Document ID: US 5753268 A

L2: Entry 7 of 21 File: USPT May 19, 1998

US-PAT-NO: 5753268

DOCUMENT-IDENTIFIER: US 5753268 A

TITLE: Anti-cholesterolemic egg, vaccine and method for production, and use

DATE-ISSUED: May 19, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stolle; Ralph J.	Lebanon	OH	N/A	N/A
Beck; Lee R.	Lebanon	OH	N/A	N/A

US-CL-CURRENT: 424/581; 426/614

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

8. Document ID: US 5753228 A

L2: Entry 8 of 21 File: USPT May 19, 1998

US-PAT-NO: 5753228

DOCUMENT-IDENTIFIER: US 5753228 A

TITLE: Method of treating parasitosis by the enteral administration of hyperimmune hen egg yolk antibodies

DATE-ISSUED: May 19, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sterling; Charles R.	Tucson	AZ	N/A	N/A
Cama; Vitaliano A.	Tucson	AZ	N/A	N/A

US-CL-CURRENT: 424/151.1; 424/130.1, 530/387.1, 530/388.6

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

9. Document ID: US 5725873 A

L2: Entry 9 of 21 File: USPT Mar 10, 1998

US-PAT-NO: 5725873

DOCUMENT-IDENTIFIER: US 5725873 A

TITLE: Method of improving the growth or the efficiency of feed conversion of an animal and compositions for use therein

DATE-ISSUED: March 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cook; Mark E.	Madison	WI	N/A	N/A
Jerome; Daria L.	Middleton	WI	N/A	N/A

US-CL-CURRENT: 424/442, 106/147.3, 106/148.1, 106/243, 424/283.1,  
426/140, 426/89, 426/92, 530/388.24, 530/388.85, 530/389.1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

10. Document ID: US 5538727 A

L2: Entry 10 of 21 File: USPT Jul 23, 1996

US-PAT-NO: 5538727

DOCUMENT-IDENTIFIER: US 5538727 A

TITLE: Anti-cholesterolemic vaccine

DATE-ISSUED: July 23, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stolle; Ralph J.	Lebanon	OH	N/A	N/A
Beck; Lee R.	Lebanon	OH	N/A	N/A

US-CL-CURRENT: 424/203.1, 424/184.1, 424/241.1, 424/256.1,  
424/257.1, 424/258.1, 424/259.1, 424/260.1, 424/261.1, 424/93.3,  
424/93.48

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

[Generate Collection](#)

Terms	Documents
4550019	21

---

[Display](#) [10](#) Documents, starting with Document: [11](#)

**Display Format:**

WEST

## Generate Collection

**Search Results - Record(s) 11 through 20 of 21 returned.**

□ 11. Document ID: US 5420253 A

L2: Entry 11 of 21 File: USPT May 30, 1995  
US-PAT-NO: 5420253  
DOCUMENT-IDENTIFIER: US 5420253 A

TITLE: Method for purifying egg yolk immunoglobulins

DATE-ISSUED: May 30, 1995

INVENTOR - INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Emery; Daryll A.	Willmar	MN	N/A	N/A
Straub; Darren E.	Willmar	MN	N/A	N/A

US-CL-CURRENT: 530/423; 424/157.1, 530/853, 530/861

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draft Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	------------	-------

12. Document ID: US 5393673 A

L2: Entry 12 of 21 File: USPT Feb 28, 1995  
US-PAT-NO: 5393673  
DOCUMENT-IDENTIFIER: US 5393673 A

**TITLE: Method for particulate reagent sample treatment**

DATE-ISSUED: February 28, 1995

**INVENTOR - INFORMATION:**

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gjerde; Douglas T.	Saratoga	CA	N/A	N/A
Wiederin; Daniel R.	Omaha	NE	N/A	N/A

US-CL-CURRENT: 436/171; 436/149, 436/154, 436/173, 436/174,  
436/178

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

13. Document ID: US 5340923 A

L2: Entry 13 of 21 File: USPT Aug 23, 1994

US-PAT-NO: 5340923  
DOCUMENT-IDENTIFIER: US 5340923 A

TITLE: Methods for making and purifying antivenoms

DATE-ISSUED: August 23, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carroll; Sean B.	Cottage Grove	WI	N/A	N/A

US-CL-CURRENT: 530/389.1, 424/172.1, 424/184.1, 424/804,  
530/391.1, 530/861

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

14. Document ID: US 5215746 A

L2: Entry 14 of 21 File: USPT Jun 1, 1993

US-PAT-NO: 5215746

DOCUMENT-IDENTIFIER: US 5215746 A

TITLE: Anti-cholesterolemic egg, vaccine and method for production, and use

DATE-ISSUED: June 1, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stolle; Ralph J.	Lebanon	OH	N/A	N/A
Beck; Lee R.	Lebanon	OH	N/A	N/A

US-CL-CURRENT: 424/157.1, 119/6.8, 424/203.1, 424/803, 426/614

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

15. Document ID: US 5130128 A

L2: Entry 15 of 21 File: USPT Jul 14, 1992

US-PAT-NO: 5130128  
DOCUMENT-IDENTIFIER: US 5130128 A

TITLE: Use of honey as vaccine

DATE-ISSUED: July 14, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stolle; Ralph J.	Oregonia	OH	N/A	N/A

US-CL-CURRENT: 424/157.1; 424/167.1, 424/172.1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

16. Document ID: US 5080895 A

L2: Entry 16 of 21 File: USPT Jan 14, 1992

US-PAT-NO: 5080895

DOCUMENT-IDENTIFIER: US 5080895 A

TITLE: Specific antibody-containing substance from eggs and method of production and use thereof

DATE-ISSUED: January 14, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tokoro; Hideo	Tokyo	N/A	N/A	JPX

US-CL-CURRENT: 424/157.1; 424/169.1, 530/367, 530/368, 530/389.5, 530/861

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

17. Document ID: US 5032518 A

L2: Entry 17 of 21 File: USPT Jul 16, 1991

US-PAT-NO: 5032518

DOCUMENT-IDENTIFIER: US 5032518 A

TITLE: Hapten-protein conjugates and the use therof

DATE-ISSUED: July 16, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Huber; Erasmus	Garching	N/A	N/A		DEX
Batz; Hans-Georg	Tutzing	N/A	N/A		DEX
von der Eltz; Herbert	Weilheim	N/A	N/A		DEX
Klein; Christian	Weilheim	N/A	N/A		DEX

US-CL-CURRENT: 435/178, 435/174, 435/188, 435/192, 435/207,  
530/363, 530/389.8, 530/395, 530/405, 530/406

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

18. Document ID: US 4894229 A

L2: Entry 18 of 21 File: USPT Jan 16, 1990

US-PAT-NO: 4894229

DOCUMENT-IDENTIFIER: US 4894229 A

TITLE: Carrier-bound immunogenic determinants and carrier therefor

DATE-ISSUED: January 16, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Polson; Alfred	Camps Bay	N/A	N/A		ZAX
Van der Merwe; Kirsten J.	Stellenbosch	N/A	N/A		ZAX

US-CL-CURRENT: 424/130.1, 424/194.1, 424/197.11, 424/804, 435/131,  
435/132, 435/137, 435/176, 435/177, 435/181, 435/252.1, 435/252.8,  
435/820, 514/2, 514/21, 514/885, 530/810

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

19. Document ID: US 4845042 A

L2: Entry 19 of 21 File: USPT Jul 4, 1989

US-PAT-NO: 4845042  
DOCUMENT-IDENTIFIER: US 4845042 A

TITLE: Adjuvant for immunization

DATE-ISSUED: July 4, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Newman; John F. E.	Grahamstown	N/A	N/A	ZAX
Hendry; Donald A.	Grahamstown	N/A	N/A	ZAX

US-CL-CURRENT: 436/545, 424/193.1, 424/196.11, 424/197.11,  
424/485, 435/5, 436/543, 436/547, 436/808, 514/773, 514/776,  
514/964, 514/965

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---

20. Document ID: US 4806348 A

L2: Entry 20 of 21 File: USPT Feb 21, 1989  
US-PAT-NO: 4806348  
DOCUMENT-IDENTIFIER: US 4806348 A

TITLE: Method for inducing antibody formation

DATE-ISSUED: February 21, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hartl; Roland	Muenster-Altheim	N/A	N/A	DEX
Kraemer; Dieter	Mainz	N/A	N/A	DEX

US-CL-CURRENT: 424/130.1, 424/193.1, 424/194.1, 424/280.1,  
530/387.1, 530/389.2, 530/389.3

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

---


Generate Collection

Terms	Documents
4550019	21

---

[Display](#) 10 Documents, starting with Document: 21

**Display Format:**



Search PubMed

for

Entrez PubMed

1: *J Med Microbiol* 1996 Aug;45(2):90-6

[Related Articles](#), [Books](#), [LinkOut](#)

PubMed Services

## A low molecular weight outer-membrane protein of *Escherichia coli* O157:H7 associated with adherence to INT407 cells and chicken caeca.

Related Resources

Zhao S, Meng J, Doyle MP, Meinersman R, Wang G, Zhao P

Center for Food Safety and Quality Enhancement, University of Georgia, Griffin 30223, USA.

Enterohaemorrhagic *Escherichia coli* (EHEC) O157:H7 and O26:H11 have been shown to produce a low mol. wt outer-membrane protein (OMP) that is unique to a few serotypes of *E. coli*. A mutant (A10) of *E. coli* O157:H7 strain HA1 deficient in the OMP was constructed by TnphoA mutagenesis and assayed for its adherent ability. Adherence of A10 to intestinal epithelial cells (INT407) was significantly less than that of its parent strain (HA1). Adherence of HA1 to INT407 cells was significantly decreased by treatment with a monoclonal antibody (4E8C12) that specifically binds to the OMP. When chickens were infected experimentally with *E. coli* O157:H7 strains, the average number of cfu of strain A10 recovered from chicken caeca was significantly less than those of strain HA1 and wild-type strain 932 at 14 and 21 days after peroral inoculation. These data suggest that the OMP of EHEC is associated with adherence of *E. coli* O157:H7 to epithelial cells in vitro and chicken caeca in vivo.

PMID: 8683557, UI: 96316949

*requested*  
Write to the Help Desk  
NCBI | NLM | NIH  
Department of Health & Human Services  
Freedom of Information Act | Disclaimer



Search PubMed

for

Go Clear

Limits Preview/Index History Clipboard

Display Abstract Save Text Order Add to Clipboard

Entrez PubMed

PubMed  
Services

Related  
Resources

1: *Appl Environ Microbiol* 1996 Mar;62(3):815-21 Related Articles, Books, LinkOut

## An rRNA approach for assessing the role of obligate amino acid-fermenting bacteria in ruminal amino acid deamination.

Krause DO, Russell JB

Section of Microbiology, Cornell University, Ithaca, New York 14853, USA.

Ruminal amino acid degradation is a nutritionally wasteful process that produces excess ruminal ammonia. Monensin inhibited the growth of monensin-sensitive, obligate amino acid-fermenting bacteria and decreased the ruminal ammonia concentrations of cattle. 16S rRNA probes indicated that monensin inhibited the growth of *Peptostreptococcus anaerobius* and *Clostridium sticklandii* in the rumen. *Clostridium aminophilum* was monensin sensitive in vitro, but *C. aminophilum* persisted in the rumen after monensin was added to the diet. An in vitro culture system was developed to assess the competition of *C. aminophilum*, *P. anaerobius*, and *C. sticklandii* with predominant ruminal bacteria (PRB). PRB were isolated from a 10(8) dilution of ruminal fluid and maintained as a mixed population with a mixture of carbohydrates. PRB did not hybridize with the probes to *C. aminophilum*, *P. anaerobius*, or *C. sticklandii*. PRB deaminated Trypticase in continuous culture, but the addition of *C. aminophilum*, *P. anaerobius*, and *C. sticklandii* caused a more-than-twofold increase in the steady-state concentration of ammonia. *C. aminophilum*, *P. anaerobius*, and *C. sticklandii* accounted for less than 5% of the total 16S rRNA and microbial protein. Monensin eliminated *P. anaerobius* and *C. sticklandii* from continuous cultures, but it could not inhibit *C. aminophilum*. The monensin resistance of *C. aminophilum* was a growth rate-dependent, inoculum size-independent phenomenon that could not be maintained in batch culture. On the basis of these results, we concluded that the feed additive monensin cannot entirely counteract the wasteful amino acid deamination of obligate amino acid-fermenting ruminal bacteria.

PMID: 8975611, UI: 97076913

Display Abstract Save Text Order Add to Clipboard



Entrez PubMed

PubMed Services

Related Resources

1: *Appl Environ Microbiol* 1993 Oct;59(10):3250-4

[Related Articles, Books](#)

## Effect of monensin on the specific activity of ammonia production by ruminal bacteria and disappearance of amino nitrogen from the rumen.

Yang CM, Russell JB

Department of Animal Science, Cornell University, Ithaca, New York.

When unadapted mixed ruminal bacteria (312 mg of protein per liter) were treated with monensin (5 mM) in vitro, the rates of ammonia production from enzymatic digests of casein, gelatin, and soy protein (0.5 g of N per liter) were decreased from 46 +/- 2 to 24 +/- 1, 20 +/- 1 to 7 +/- 1, and 40 +/- 2 to 18 +/- 2 nmol/mg of protein per min, respectively. Monensin also caused a decrease in ammonia production in vivo. Nonlactating dairy cows which were fed 0.56 kg of timothy hay 12 times per day had a steady-state ruminal ammonia concentration of 2.7 +/- 0.1 mM, and the ammonia concentration decreased to 1.2 +/- 0.2 mM when monensin (350 mg/day) was added to the diet. The decrease in ammonia production was associated with a 10-fold reduction (4.1 x 10(6) versus 4.2 x 10(5)/ml) in the most probable number of ammonia-producing ruminal bacteria that could use protein hydrolysate as an energy source. Monensin had little effect on the most probable number of carbohydrate-utilizing ruminal bacteria (6.5 versus 7.0 x 10(8)/ml). The addition of protein hydrolysates (560 g) to the rumen caused a rapid increase in the ammonia concentration, but this increase was at least 30% lower when the animals were fed monensin. (ABSTRACT TRUNCATED AT 250 WORDS)

PMID: 8250552, UI: 94071438

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Search PubMed for           

Entrez PubMed

 1: *J Anim Sci* 1993 Dec;71(12):3470-6

Related Articles, Books

PubMed  
ServicesRelated  
Resources

## The effect of monensin supplementation on ruminal ammonia accumulation in vivo and the numbers of amino acid-fermenting bacteria.

**Yang CM, Russell JB**

Section of Microbiology, Cornell University, Ithaca, NY 14853.

When nonlactating Holstein cows (685 +/- 59 kg) were fed chopped timothy hay (9% CP, 7.0 kg/d) 12 times daily, the steady-state ruminal ammonia concentration was 2.6 mM, and the specific activity of ammonia production by mixed ruminal bacteria was 27.4 nmol/mg of protein-1.min-1. The addition of soybean meal (53% CP, 1 or 2 kg/d) to the basal diet caused a linear increase in ruminal ammonia (7.0 and 12.4 mM, respectively;  $P < .001$ ), but there was only a small increase in the specific activity of ammonia production (30.7 and 33.8 nmol/mg of protein-1.min-1, respectively;  $P < .05$ ). The addition of monensin (350 mg/d) to the diets caused more than a 30% decrease ( $P < .01$ ) in ruminal ammonia at all levels of soybean supplementation, and there was a similar decrease ( $P < .001$ ) in the specific activity of ammonia production. Before monensin addition, the most probable number of bacteria that could utilize peptides and amino acids, but not carbohydrates, as an energy source for growth was 5.8 to  $7.0 \times 10^6$ /mL. When monensin was added to the diets, these bacteria decreased ( $P < .001$ ) nearly 10-fold. Based on these results, it seemed that monensin inhibited highly active amino acid-fermenting ruminal bacteria, and this inhibition, in turn, decreased ruminal amino acid deamination and ammonia production. Because monensin did not increase soluble protein, peptides, or amino acids in ruminal fluid, it did not seem that the decrease in ammonia increased flow of dietary amino N to the lower gut. (ABSTRACT TRUNCATED AT 250 WORDS)

PMID: 8294302, UI: 94124374

     [Write to the Help Desk](#)



Search PubMed

for

Entrez PubMed

1: *J Gen Microbiol* 1980 Dec;121(Pt. 2):387-400

Related Articles, Books

PubMed  
Services

Related  
Resources

## The association of the O18, K1 and H7 antigens and the ColV plasmid of a strain of *Escherichia coli* with its virulence and immunogenicity.

Smith HW, Huggins MB

From an O18ac:K1:H7 ColV+ strain of *Escherichia coli* (designated MW) that had caused meningitis in a human baby, mutant forms were isolated that lacked different combinations of its O, K and H antigens and its ColV plasmid. These characters were also transmitted by conjugation to *E. coli* K12 and the virulence, immunogenicity and other properties of the different forms of both strains were studied. All the forms of the MW strain that lacked either the O18 or K1 antigens or the ColV plasmid, but not the H7 antigen, were much less virulent for chickens and mice than the parent form of MW. Another form derived by N-methyl-N'-nitro-N-nitrosoguanidine (NTG) treatment of the parent strain and that possessed all these four characters was also much less virulent. Some of the forms of the K12 strain to which the characters had been transferred were slightly more virulent than the K12 parent, but the virulence of all of them, including one possessing the O18 and K1 antigens and the ColV plasmid, did not approach that of the MW parent. Pathogenesis studies in chickens and colostrum-deprived calves revealed that the loss of virulence exhibited by the forms of the MW strain that lacked O18, K1 and ColV and by the NTG-derived form was associated with decreased ability to invade the body. This was also the reason for the low virulence of the forms of the K12 strain that had acquired these characters. Possession of both the O18 and K1 antigens was largely responsible for the ability of the different forms of the MW strain to survive in fresh chicken serum; organisms of K12 that possessed the K1 antigen survived as long as those of the parent form of the MW strain. A substantial degree of immunity against lethal infection with the parent form of the MW strain was produced in chickens and mice by all the forms of the MW and K12 strains that possessed the O18 antigen. The K1 and H7 antigens and the ColV plasmid produced no detectable immunity.

PMID: 7021764, UI: 81266145



Search PubMed

 for

Go

Clear

Limits

Preview/Index

History

Clipboard

Display

Abstract

Save

Text

Order

Add to Clipboard

Entrez PubMed

PubMed  
ServicesRelated  
Resources 1: *Infect Immun* 1998 Sep;66(9):4560-3

Related Articles, Books, LinkOut

FREE full-text article at  
cat.usm.org**Escherichia coli O157:H7 requires intimin for enteropathogenicity in calves.****Dean-Nystrom EA, Bosworth BT, Moon HW, O'Brien AD**

Enteric Diseases and Food Safety Research Unit, National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, Iowa 50010, USA. [enystrom@nadc.ars.usda.gov](mailto:enystrom@nadc.ars.usda.gov)

Enterohemorrhagic *Escherichia coli* (EHEC) strains require intimin to induce attaching and effacing (A/E) lesions in newborn piglets. Infection of newborn calves with intimin-positive or intimin-negative EHEC O157:H7 demonstrated that intimin is needed for colonization, A/E lesions, and disease in cattle. These results suggest that experiments to determine if intimin-based vaccines reduce O157:H7 levels in cattle are warranted.

PMID: 9712821, UI: 98380418

Display

Abstract

Save

Text

Order

Add to Clipboard

Write to the Help DeskNCBI | NLM | NIHDepartment of Health & Human ServicesFreedom of Information Act | Disclaimer*fragmented*